Human Organoid and Supporting Technologies for Cancer and Toxicological Research

Sekine, Keisuke

doi:10.3389/fgene.2021.759366

Cited by 5 publications

(4 citation statements)

References 66 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vitro models of pancreatic cancer create the primary site of cancer. The 3D organoid structures are currently being investigated to evaluate the pathology and migration of primary site pancreatic cancer [ 133 , 134 ]. Recently, 3D organoids developed from patient tissue sources or genetically engineered mouse models have been developed as tools for patient-specific therapies of primary site pancreatic cancer and are suitable as preclinical models of pancreatic cancer [ 135 ].…”

Section: Cancer Metastasis 3d In Vitro Modelsmentioning

confidence: 99%

Current Advances in the Use of Tissue Engineering for Cancer Metastasis Therapeutics

Katti,

Jasuja

2024

Polymers

View full text Add to dashboard Cite

Cancer is a leading cause of death worldwide and results in nearly 10 million deaths each year. The global economic burden of cancer from 2020 to 2050 is estimated to be USD 25.2 trillion. The spread of cancer to distant organs through metastasis is the leading cause of death due to cancer. However, as of today, there is no cure for metastasis. Tissue engineering is a promising field for regenerative medicine that is likely to be able to provide rehabilitation procedures to patients who have undergone surgeries, such as mastectomy and other reconstructive procedures. Another important use of tissue engineering has emerged recently that involves the development of realistic and robust in vitro models of cancer metastasis, to aid in drug discovery and new metastasis therapeutics, as well as evaluate cancer biology at metastasis. This review covers the current studies in developing tissue-engineered metastasis structures. This article reports recent developments in in vitro models for breast, prostate, colon, and pancreatic cancer. The review also identifies challenges and opportunities in the use of tissue engineering toward new, clinically relevant therapies that aim to reduce the cancer burden.

show abstract

Section: Cancer Metastasis 3d In Vitro Modelsmentioning

confidence: 99%

Current Advances in the Use of Tissue Engineering for Cancer Metastasis Therapeutics

Katti,

Jasuja

2024

Polymers

View full text Add to dashboard Cite

show abstract

“…It is promising that tissue and organ engineering enable patterning human tissues composed of different cell types with a similar physiological microenvironment that can be maintained over prolonged periods. Moreover, this might contribute to developing organoids with greater homogeneity and vascularization in the future [ 257 , 258 , 259 ].…”

Section: Bioengineered Organoids and 3d Bioprintingmentioning

confidence: 99%

“…For example, in prostate cancer patients, the BRCA2-RB1 deletion was found to alter epithelial-stromal and increase cancer aggressiveness. In brain cancers, with gene editing and the use of neoplastic cerebral organoids, combinations of mutations that lead to neuroectodermal tumors were identified [ 132 , 257 ]. Moreover, CRISPR–Cas9 is used as reverse-engineering to understand the serrated neoplasia pathway in organoid-based colorectal cancer [ 258 ].…”

Section: Gene Editing Technologies In Organoidsmentioning

confidence: 99%

Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems

Silva-Pedrosa

Salgado

Ferreira

2023

Cells

View full text Add to dashboard Cite

Cellular models have created opportunities to explore the characteristics of human diseases through well-established protocols, while avoiding the ethical restrictions associated with post-mortem studies and the costs associated with researching animal models. The capability of cell reprogramming, such as induced pluripotent stem cells (iPSCs) technology, solved the complications associated with human embryonic stem cells (hESC) usage. Moreover, iPSCs made significant contributions for human medicine, such as in diagnosis, therapeutic and regenerative medicine. The two-dimensional (2D) models allowed for monolayer cellular culture in vitro; however, they were surpassed by the three-dimensional (3D) cell culture system. The 3D cell culture provides higher cell–cell contact and a multi-layered cell culture, which more closely respects cellular morphology and polarity. It is more tightly able to resemble conditions in vivo and a closer approach to the architecture of human tissues, such as human organoids. Organoids are 3D cellular structures that mimic the architecture and function of native tissues. They are generated in vitro from stem cells or differentiated cells, such as epithelial or neural cells, and are used to study organ development, disease modeling, and drug discovery. Organoids have become a powerful tool for understanding the cellular and molecular mechanisms underlying human physiology, providing new insights into the pathogenesis of cancer, metabolic diseases, and brain disorders. Although organoid technology is up-and-coming, it also has some limitations that require improvements.

show abstract

“…The substantial financial and logistical challenges inherent in the production and transportation of source cells accentuate the need for thorough management to prevent loss through negligence, thus raising concerns pertaining to safety and efficacy in manufacturing, packaging, transportation, storage, and manipulation of source cells. The growing application of organoids in medical research ( 3 - 6 ) worldwide is attributed to their potential in recapitulating bodily functions. In this context, standardization of source cells ( 7 ) is viewed as a crucial step toward enhancing the quality and uniformity of organoid products ( 8 ) and their widespread dissemination.…”

Section: Introductionmentioning

confidence: 99%

Guidelines for Packaging, Transport, and Storage of Source Cells for Organoids

Lee,

Kwon,

Lee

et al. 2024

Int J Stem Cells

View full text Add to dashboard Cite

This report presents guidelines for the systematic management of packaging, storage, transportation, and traceability of source cells used for organoid research. Given the important role of source cells in organoid studies, it is important to ensure the preservation of their quality and integrity throughout transportation and distribution processes. The proposed guidelines, therefore, call for a cohesive strategy through these stages to minimize the risks of contamination, deterioration, and loss–threats that significantly compromise the safety, efficacy, and efficiency of source cells. Central to these guidelines is the quality control measures that include roles and responsibilities across the entire supply chain, with recommendations specific to packaging materials, transportation facilities, and storage management. Furthermore, the need for an integrated management system is emphasized, spanning from source cell collection to the final application. This system is crucial for maintaining the traceability and accountability of source cells, facilitating the sharing, distribution, and utilization on a global scale, and supporting to advance organoid research and development.

show abstract

Human Organoid and Supporting Technologies for Cancer and Toxicological Research

Cited by 5 publications

References 66 publications

Current Advances in the Use of Tissue Engineering for Cancer Metastasis Therapeutics

Current Advances in the Use of Tissue Engineering for Cancer Metastasis Therapeutics

Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems

Guidelines for Packaging, Transport, and Storage of Source Cells for Organoids

Contact Info

Product

Resources

About